RARE MEXC RealStocks
Own real RARE shares through MEXC's regulated brokerage partner.
Suitable for long-term holding.
- Own the actual shares
- Receive dividends and voting rights
- Buy fractional shares starting at $1
Last updated: 2026-11-13 15:05:20. Prices reflect the latest regular market data. Stock price data is sourced from Massive.
Ultragenyx Pharmaceutical Inc. (RARE) operates in the PHARMACEUTICAL PREPARATIONS sector and is listed on NASDAQ. The stock is currently priced at $15.92, with a market capitalization of $1.66B and a P/E ratio of --. Over the past 52 weeks, its price has ranged from $12.73 to $39.89. This page covers its latest market performance, valuation, price trends and company information.
$1.66B | |
$16.30 | |
$16.54 | |
$15.89 | |
$16.27 | |
88.61K | |
4.56M | |
-- | |
$39.89 | |
$12.73 | |
-- | |
-- |
Ultragenyx Pharmaceutical Inc. (RARE) is currently trading at $15.92 as of 2026-11-13 15:03:00, down 0.31% ($0.05) from the previous close of $16.27
During today's regular trading session, RARE has traded between $15.89 and $16.54, with a trading volume of 88.61K shares. The current price is near the lower end of today's range.
Over the past seven days, Ultragenyx Pharmaceutical Inc. (RARE) moved from $15.57 to $15.92, representing a gain of 2.24% ($0.35).
The stock traded between $15.12 and $17.12 during the period. The latest price is near the middle of the 7-day range, indicating moderate upward.
The average daily volume was 3.41 million shares, down versus the previous seven-day period, indicating lower trading activity.
Position in Range: 11.7%
RARE is currently trading at $15.92, placing it 11.7% of the way from its 52-week low of $12.73 to its 52-week high of $39.89. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
Ultragenyx Pharmaceutical Inc is a USA-based biopharmaceutical company. The company identifies, acquires, develops, and commercializes novel products for the treatment of serious, rare, and ultra-rare diseases, with a focus on debilitating genetic conditions. Its medicine portfolio includes Crysvita, Dojolvi, and Mepsevii. Crysvita is indicated for the treatment of X-linked hypophosphatemia (XLH) in adult and pediatric patients aged one year and older. Mepsevii is indicated for pediatric and adult patients for the treatment of Mucopolysaccharidosis VII. The company operates across North America, Latin America, Europe, the Middle East and Africa, and Asia-Pacific, with the majority of its revenue generated from North America.
| Industry | PHARMACEUTICAL PREPARATIONS |
| Employees | 1,371 |
| Exchange | NASDAQ |
| Company Website |
Eligible investors can buy real shares of Ultragenyx Pharmaceutical Inc. (RARE) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.
Stock prices and market data on this page, including price changes and market status, are provided by Massive and other third-party news and data platforms. Market data may be delayed and may differ from prices on other platforms or the prices at which trades are executed on MEXC. MEXC does not guarantee the accuracy, completeness, or timeliness of third-party data. MEXC offers trading products related to RARE, including Stocks, Tokenized Stocks, and Stock Futures.
The stock price information displayed on this page is provided for reference purposes only and may be delayed or differ from real-time market data. Prices, charts, and related metrics do not constitute investment advice and should not be relied upon for trading or investment decisions. MEXC is not responsible for any losses incurred based on the stock price information provided on this page. Please refer to official market sources or consult licensed financial professionals before making any investment decisions.
Estimate the value between RARE shares and USD.
RARE Shares to USD
1.00 RARE shares = 15.918 USD
Calculations are estimates based on the latest available price and are for reference only.